Our Science

Synthetic gene parts, circuits and delivery vectors are designed using computation-assisted methods to build programmable gene therapies.

Synov oncolytic virus platform

Synov is an oncolytic adenovirus therapy platform developed by SyngenTech for logical gene circuit-based regulation. Its first product, Synov1.1, is a gene therapy product targeting alpha-fetoprotein positive solid tumours. This innovative drug is designed with the idea of synthetic biology and uses artificial gene circuits to identify multiple biomarkers in tumour cells, regulate their targeting tumour specificity, secrete immune factors to stimulate the anti-tumour immune response and improve tumour killing ability and clinical application safety. By October 2021, SynOV1.1 has obtained the approval for Phase I clinical trial from China's National Medical Products Administration (NMPA) and the United States Food and Drug Administration (FDA). At present, the Phase I clinical trial in China is in progress.

mRNA sequence design and optimization

mRNA is an important drug carrier form that expresses effector proteins through translation. Different mRNA sequences have large differences in stability, translation efficiency and immunogenicity. We use artificial intelligence models (AI) to optimize the mRNA sequences. The optimized mRNA can produce higher levels of effector proteins, thereby achieving lower mRNA dosage, lower safety risks, and higher efficacy.

Circular RNA drug platform

Circular RNA is an important drug carrier form that has multiple advantages compared to mRNA: (1) Better stability and longer protein expression duration; (2) No need for capping, tailing and nucleotide modification; (3) Can achieve higher expression and precise regulation through optimize IRES. We have established a mature circular RNA design and production platform, a high-expression IRES sequence database and patented IRES regulation technology.